Sensei Biotherapeutics (NYSE: SNSE) — Company Overview, News & Financial Data
Sensei Biotherapeutics is a biopharmaceutical company focused on next-generation immunotherapies for cancer using its ImmunoPhage™ platform.
Sensei Biotherapeutics
Sensei Biotherapeutics (NASDAQ:SNSE) is a biopharmaceutical company focused on the development of next-generation immunotherapies for cancer and infectious diseases. The company's work revolves around its proprietary ImmunoPhage™ platform and its novel monoclonal antibody and T-cell receptor discovery platform, aimed at tailoring treatments to harness the body's immune system more effectively. Their pipeline includes multiple projects in various stages of research and clinical development, designed to achieve better outcomes for patients with unmet medical needs. Sensei Biotherapeutics is on a mission to transform cancer treatment paradigms and improve patient lives through groundbreaking scientific innovation.
Snapshot
Operations
Products and/or services of Sensei Biotherapeutics
- Immuno-oncology therapeutics harnessing the immune system to fight cancer, focusing on novel treatments for various tumor types.
- VISTA checkpoint inhibitors targeting the V-set immunoregulatory domain to augment cancer immunotherapy efficacy.
- Precision medicine approach, using genomic data to tailor unique treatment strategies for cancer patients.
- Research on bacteriophage-based vaccines aimed at stimulating the immune system against cancer.
- Pipeline of monoclonal antibodies designed for specific tumor-associated antigens, improving targeted therapy options.
- Collaborative research partnerships with academic institutions and biotech firms to speed up the development of innovative cancer treatments.
Sensei Biotherapeutics executive team
- Mr. Christopher W. Gerry J.D.President, General Counsel & Secretary
- Mr. Josiah CraverSenior VP of Finance, Principal Financial Officer & Principal Accounting Officer
- Ms. Lora PikeVice President of Investor Relations & Communications